Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) EBITDA (2018 - 2019)

DiaMedica Therapeutics' EBITDA history spans 2 years, with the latest figure at -$2.5 million for Q4 2019.

  • For Q4 2019, EBITDA fell 26.61% year-over-year to -$2.5 million; the TTM value through Dec 2019 reached -$10.6 million, down 85.68%, while the annual FY2025 figure was -$32.7 million, 34.03% down from the prior year.
  • EBITDA reached -$2.5 million in Q4 2019 per DMAC's latest filing, down from -$2.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$650000.0 in Q1 2018 to a low of -$3.2 million in Q1 2019.